scholarly journals COVID 19 Antibody Detection using Lateral Flow Assay Tests in a Cohort of Convalescent Plasma Donors

2020 ◽  
Author(s):  
Brett Ragnesola ◽  
Daniel Jin ◽  
Chris C. Lamb ◽  
Beth H. Shaz ◽  
Christopher D. Hillyer ◽  
...  
Keyword(s):  
New York ◽  
Relative Risk ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Antibody Detection ◽  
Specific Antibodies ◽  
Testing Platform ◽  
Specific Igg ◽  
Disease Exposure ◽  
Donor Plasma

Abstract Objective: COVID19 has caused a global and ongoing pandemic. The need for population seroconversion data is apparent to monitor and respond to the pandemic. Using a lateral flow assay (LFA) testing platform, the seropositivity in 63 New York Blood Center (NYBC)Convelescent Plasma (CP) donor samples were evaluated for the presence of COVID19 specific IgG and IgM.Results: CP donors showed diverse antibody result.Convalescent donor plasma contains SARS-CoV-2 specific antibodies. Weak antibody bands may identify low titer CP donors.LFA tests can identify antibody positive individuals that have recovered from COVID19. Confirming suspected cases using antibody detection could help inform the patient and the community as to the relative risk to future exposure and a better understanding of disease exposure.

scholarly journals Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis

2019 ◽  
Vol 57 (9) ◽  
Author(s):  
Elizabeth Stucky Hunter ◽  
Malcolm D. Richardson ◽  
David W. Denning
Keyword(s):  
United Kingdom ◽  
Line Intensity ◽  
Test Line ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Antibody Detection ◽  
Resource Constrained ◽  
Pulmonary Aspergillosis ◽  
Chronic Pulmonary Aspergillosis ◽  
Specific Igg

ABSTRACT Detecting Aspergillus-specific IgG is critical to diagnosing chronic pulmonary aspergillosis (CPA). Existing assays are often cost- and resource-intensive and not compatible with resource-constrained laboratory settings. LDBio Diagnostics has recently commercialized a lateral flow assay based on immunochromatographic technology (ICT) that detects Aspergillus antibodies (IgG and IgM) in less than 30 min, requiring minimal laboratory equipment. A total of 154 CPA patient sera collected at the National Aspergillosis Centre (Manchester, United Kingdom) and control patient sera from the Peninsula Research Bank (Exeter, United Kingdom) were evaluated. Samples were applied to the LDBio Aspergillus ICT lateral flow assay, and results were read both visually and digitally. Results were compared with Aspergillus IgG titers in CPA patients, measured by ImmunoCAP-specific IgG assays. For proven CPA patients versus controls, sensitivity and specificity for the LDBio Aspergillus ICT were 91.6% and 98.0%, respectively. In contrast, the routinely used ImmunoCAP assay exhibited 80.5% sensitivity for the same cohort (cutoff value, 40 mg of antigen-specific antibodies [mgA]/liter). The assay is easy to perform but challenging to read when only a very faint band is present (5/154 samples tested). The ImmunoCAP Aspergillus IgG titer was also compared with the Aspergillus ICT test line intensity or rate of development, with weak to moderate correlations. The Aspergillus ICT lateral flow assay exhibits excellent sensitivity for serological diagnosis of CPA. Quantifying IgG from test line intensity measurements is not reliable. Given the short run time, simplicity, and limited resources needed, the LDBio Aspergillus ICT is a suitable diagnostic tool for CPA in resource-constrained settings.

scholarly journals SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence

2020 ◽  
Author(s):  
Gerco den Hartog ◽  
Rutger M. Schepp ◽  
Marjan Kuijer ◽  
Corine GeurtsvanKessel ◽  
Josine van Beek ◽  
...  
Keyword(s):  
Multiplex Assay ◽  
Spike Protein ◽  
Antibody Detection ◽  
Test Results ◽  
Detailed Understanding ◽  
Protein Subunits ◽  
Specific Antibodies ◽  
Single Antigen ◽  
Specific Igg ◽  
Kinetics Of

ABSTRACTBackgroundThe COVID-19 pandemic demands detailed understanding of the kinetics of antibody production induced by infection with SARS-CoV-2. We aimed to develop a high throughput multiplex assay to detect antibodies to SARS-CoV-2 to assess immunity to the virus in the general population.MethodsSpike protein subunits S1 and RBD, and Nucleoprotein were coupled to distinct microspheres. Sera collected before the emergence of SARS-CoV-2 (N=224), and of non-SARS-CoV-2 influenza-like illness (N=184), and laboratory-confirmed cases of SARS-CoV-2 infection (N=115) with various severity of COVID-19 were tested for SARS-CoV-2-specific concentrations of IgG.ResultsOur assay discriminated SARS-CoV-2-induced antibodies and those induced by other viruses. The assay obtained a specificity between 95.1 and 99.0% with a sensitivity ranging from 83.6-95.7%. By merging the test results for all 3 antigens a specificity of 100% was achieved with a sensitivity of at least 90%. Hospitalized COVID-19 patients developed higher IgG concentrations and the rate of IgG production increased faster compared to non-hospitalized cases.ConclusionsThe bead-based serological assay for quantitation of SARS-CoV-2-specific antibodies proved to be robust and can be conducted in many laboratories. Finally, we demonstrated that testing of antibodies against different antigens increases sensitivity and specificity compared to single antigen-specific IgG determination.

scholarly journals Performance of Commercially Available Rapid Serological Assays for The Detection of SARS-CoV-2 Antibodies

2020 ◽  
Author(s):  
Anwar M Hashem ◽  
Rowa Y Y Rowa Y Alhabbab ◽  
Abdullah Algaissi ◽  
Mohamed A Alfaleh ◽  
Sharif Hala ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Significant Variation ◽  
High Specificity ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Specific Antibodies ◽  
Time Points ◽  
Igm Antibodies ◽  
Specific Igg ◽  
High Degree

Abstract Background: The Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. Although several commercial SARS-CoV-2 rapid serological assays have been developed, little is known about their performance and accuracy in detecting SARS-CoV-2 specific antibodies in COVID-19 patient samples. Method: We have evaluated the performance of seven commercially available rapid lateral flow immunoassay (LFIA) serological assays obtained from different manufacturers, and compared them to in-house developed and validated ELISA assays for the detection of SARS-CoV-2 specific IgG and IgM antibodies in COVID-19 patients. Results: While all evaluated LFIA assays showed high specificity, our data showed a significant variation in sensitivity of these assays in which it ranged from 0 to 54% for samples collected early during infection (3-7 days post symptoms onset) and from 54 to 88% for samples collected at later time points during infection (8-27 days post symptoms onset). Conclusion: Commercially available LFIA assays for detection of SARS-CoV-2 specific antibodies may be specific and show high degree of variation in their sensitivity. Further evaluations and validation of rapid serological assays is needed before being routinely used in detecting IgM and IgG in COVID-19 patients.

scholarly journals SARS-CoV-2–Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

2020 ◽  
Vol 222 (9) ◽  
pp. 1452-1461 ◽  
Author(s):  
Gerco den Hartog ◽  
Rutger M Schepp ◽  
Marjan Kuijer ◽  
Corine GeurtsvanKessel ◽  
Josine van Beek ◽  
...  
Keyword(s):  
Multiplex Assay ◽  
Spike Protein ◽  
Antibody Detection ◽  
Receptor Binding Domain ◽  
Test Results ◽  
Protein Subunits ◽  
Specific Antibodies ◽  
Single Antigen ◽  
Specific Igg ◽  
Kinetics Of

Abstract Background The COVID-19 pandemic necessitates better understanding of the kinetics of antibody production induced by infection with SARS-CoV-2. We aimed to develop a high-throughput multiplex assay to detect antibodies to SARS-CoV-2 to assess immunity to the virus in the general population. Methods Spike protein subunits S1 and receptor binding domain, and nucleoprotein were coupled to microspheres. Sera collected before emergence of SARS-CoV-2 (n = 224) and of non-SARS-CoV-2 influenza-like illness (n = 184), and laboratory-confirmed cases of SARS-CoV-2 infection (n = 115) with various severities of COVID-19 were tested for SARS-CoV-2–specific IgG concentrations. Results Our assay discriminated SARS-CoV-2–induced antibodies and those induced by other viruses. The assay specificity was 95.1%–99.0% with sensitivity 83.6%–95.7%. By merging the test results for all 3 antigens a specificity of 100% was achieved with a sensitivity of at least 90%. Hospitalized COVID-19 patients developed higher IgG concentrations and the rate of IgG production increased faster compared to nonhospitalized cases. Conclusions The bead-based serological assay for quantitation of SARS-CoV-2–specific antibodies proved to be robust and can be conducted in many laboratories. We demonstrated that testing of antibodies against multiple antigens increases sensitivity and specificity compared to single-antigen–specific IgG determination.

scholarly journals Lateral Flow Assay for the Detection of African Swine Fever Virus Antibodies Using Gold Nanoparticle-Labeled Acid-Treated p72

2022 ◽  
Vol 9 ◽  
Author(s):  
Wenzhuang Zhu ◽  
Kaiwen Meng ◽  
Yueping Zhang ◽  
Zhigao Bu ◽  
Dongming Zhao ◽  
...  
Keyword(s):  
Gold Nanoparticle ◽  
African Swine Fever Virus ◽  
African Swine Fever ◽  
High Sensitivity ◽  
Lateral Flow ◽  
Fever Virus ◽  
Lateral Flow Assay ◽  
Diagnostic Methods ◽  
Detection Methods ◽  
Antibody Detection

African swine fever is a widespread and highly contagious disease in the porcine population, which is caused by African swine fever virus (ASFV). The PCR and ELISA detection methods are the main conventional diagnostic methods for ASFV antigen/antibody detection in the field. However, these methods have limitations of expensive equipment, trained technicians, and time-consuming results. Thus, a rapid, inexpensive, accurate and on-site detection method is urgently needed. Here we describe a double-antigen-sandwich lateral-flow assay based on gold nanoparticle-conjugated ASFV major capsid protein p72, which can detect ASFV antibody in serum samples with high sensitivity and specificity in 10 min and the results can be determined by naked eyes. A lateral flow assay was established by using yeast-expressed and acid-treated ASFV p72 conjugated with gold nanoparticles, which are synthesized by seeding method. A high coincidence (97.8%) of the assay was determined using clinical serum compared to a commercial ELISA kit. In addition, our lateral flow strip can detect as far as 1:10,000 diluted clinically positive serum for demonstration of high sensitivity. In summary, the assay developed here was shown to be rapid, inexpensive, accurate and highly selective. It represents a reliable method for on-site ASFV antibody detection and may help to control the ASFV pandemic.

scholarly journals COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Brett Ragnesola ◽  
Daniel Jin ◽  
Christopher C. Lamb ◽  
Beth H. Shaz ◽  
Christopher D. Hillyer ◽  
...  
Keyword(s):  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Antibody Detection

scholarly journals Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific Antibodies

2020 ◽  
Author(s):  
Jan Pietschmann ◽  
Nadja Vöpel ◽  
Holger Spiegel ◽  
Hans-Joachim Krause ◽  
Florian Schröper
Keyword(s):  
Magnetic Nanoparticles ◽  
Human Serum ◽  
Point Of Care ◽  
Lateral Flow ◽  
Antibody Detection ◽  
Diagnostic Systems ◽  
Antibody Testing ◽  
Detection Range ◽  
Specific Antibodies ◽  
Detection Technology

AbstractSARS-CoV-2 causes ongoing infections worldwide, and identifying people with immunity is becoming increasingly important. Available point-of-care diagnostic systems as lateral flow assays have high potential for fast and easy on-site antibody testing but are lacking specificity, sensitivity or possibility for quantitative measurements. Here, a new point-of-care approach for SARS-CoV-2 specific antibody detection in human serum based on magnetic immuno-detection is described and compared to standard ELISA. For magnetic immuno-detection, immunofiltration columns were coated with a SARS-CoV-2 spike protein peptide. SARS-CoV-2 peptide reactive antibodies, spiked at different concentrations into PBS and human serum, were rinsed through immunofiltration columns. Specific antibodies were retained within the IFC and labelled with an isotype specific biotinylated antibody. Streptavidin-functionalized magnetic nanoparticles were applied to label the secondary antibodies. Enriched magnetic nanoparticles were then detected by means of frequency magnetic mixing detection technology, using a portable magnetic read-out device. Measuring signals corresponded to the amount of SARS-CoV-2 specific antibodies in the sample. Our preliminary magnetic immuno-detection setup resulted in a higher sensitivity and broader detection range and was four times faster than ELISA. Further optimizations could reduce assay times to that of a typical lateral flow assay, enabling a fast and easy approach, well suited for point-of-care measurements without expensive lab equipment.

Sign in / Sign up

Export Citation Format

Share Document